Imipenem/Cilastatin Aptapharma (Cilastatin, Imipenem)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin, co‑administered, blocks renal dehydropeptidase I, preventing enzymatic breakdown of imipenem and enhancing its urinary concentration and overall antimicrobial activity.

The specific dose and dosing interval are determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. No standardized dosing information is provided here.

Safety data for imipenem/cilastatin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Imipenem/cilastatin offers a broad spectrum of activity against Gram‑negative, Gram‑positive, and anaerobic bacteria, similar to other carbapenems like meropenem. Its combination with cilastatin protects the drug from renal degradation, potentially allowing higher urinary concentrations, which can be advantageous in certain infections.

The product should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Maintaining the cold chain ensures drug stability and potency until administration.

Imipenem/Cilastatin Aptapharma is supplied as an injectable solution for intravenous infusion. It is administered by a healthcare professional, typically diluted in an appropriate compatible IV fluid and infused over a specified period as directed by the prescriber.

Serious risks include the potential for seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and renal toxicity. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or other beta‑lactam antibiotics should avoid this medication. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving valproic acid, unless the prescriber determines the benefits outweigh the risks.